Cyclosporin A Production from Tolipocladium inflatumNida Tabassum Khan*
Department of Biotechnology, Faculty of Life Sciences and Informatics, Balochistan University of Information Technology Engineering and Management Sciences, (BUITEMS), Quetta, Pakistan
- Corresponding Author:
- Nida Tabassum Khan
Department of Biotechnology
Faculty of Life Sciences and Informatics
Balochistan University of Information Technology Engineering and Management Sciences
(BUITEMS), Quetta, Pakistan
E-mail: [email protected]
Received Date: July 12, 2017; Accepted Date: August 04, 2017; Published Date: August 10, 2017
Citation: Khan NT (2017) Cyclosporin A Production from Tolipocladium inflatum. Gen Med (Los Angeles) 5:294. doi:10.4172/2327-5146.1000294
Copyright: © 2017 Khan NT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The demand for this drug in the US market is estimated at $450 million. Cyclosporin A demand is increasing worldwide because of its enhanced anti-fungal and anti-viral potency that it can be used to treat diseases like canine skin disease and rheumatoid arthritis. Cyclosporin A is easily produced from the fungus Tolipocladium inflatum by the process of fermentation in a bioreactor under optimum reaction conditions to obtain maximum yield of the antibiotic. Currently attempts have been made to increase its solubility to enhance its absorption in the body.